FDA clears Baxter next-gen bone graft substitute

July 9, 2020

The FDA has issued 510(k) clearance for Baxter International’s (NYSE:BAX) Altapore Shape Bioactive Bone Graft, its next-generation bone graft substitute product line.

The company says Altapore Shape is designed to enhance bone growth and help achieve fusion, leading to reduced pain and improved patient outcomes.

https://seekingalpha.com/news/3589847-fda-clears-baxter-next-gen-bone-graft-substitute